Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease

John E. Levine, Sophie Paczesny, Shin Mineishi, Thomas Braun, Sung W. Choi, Raymond J. Hutchinson, Dawn Jones, Yasser Khaled, Carrie L. Kitko, Daniel Bickley, Oleg Krijanovski, Pavan Reddy, Gregory Yanik, James L M Ferrara

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Graft-versus-host disease (GVHD) is a principal cause of morbidity following allogeneic hematopoietic cell transplantation (HCT). Standard therapy for GVHD, high-dose steroids, results in complete responses (CRs) in 35% of patients. Because tumor necrosis factor-α (TNFα) is an important effector of experimental GVHD, we treated patients with newonset GVHD with steroids plus the TNFα inhibitor etanercept on a previously reported pilot trial (n = 20) and a phase 2 trial (n = 41). We compared their outcomes with those of contemporaneous patients with GVHD (n = 99) whose initial therapy was steroids alone. Groups were similar with respect to age, conditioning, donor, degree of HLA match, and severity of GVHD at onset. Patients treated with etanercept were more likely to achieve CR than were patients treated with steroids alone (69% vs 33%; P <.001). This difference was observed in HCT recipients of both related donors (79% vs 39%; P = .001) and unrelated donors (53% vs 26%; P <.001). Plasma TNFR1 levels, a biomarker for GVHD activity, were elevated at GVHD onset and decreased significantly only in patients with CR. We conclude that etanercept plus steroids as initial therapy for acute GVHD results in a substantial majority of CRs. This trial was referenced at www.clinicaltrials.gov as NCT00141713.

Original languageEnglish (US)
Pages (from-to)2470-2475
Number of pages6
JournalBlood
Volume111
Issue number4
DOIs
StatePublished - Feb 15 2008
Externally publishedYes

Fingerprint

Methylprednisolone
Graft vs Host Disease
Grafts
Steroids
Therapeutics
Cell Transplantation
Tumor Necrosis Factor-alpha
Tissue Donors
Receptors, Tumor Necrosis Factor, Type I
Transplantation (surgical)
Etanercept
Unrelated Donors
Biomarkers
Morbidity
Plasmas

ASJC Scopus subject areas

  • Hematology

Cite this

Levine, J. E., Paczesny, S., Mineishi, S., Braun, T., Choi, S. W., Hutchinson, R. J., ... Ferrara, J. L. M. (2008). Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood, 111(4), 2470-2475. https://doi.org/10.1182/blood-2007-09-112987

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. / Levine, John E.; Paczesny, Sophie; Mineishi, Shin; Braun, Thomas; Choi, Sung W.; Hutchinson, Raymond J.; Jones, Dawn; Khaled, Yasser; Kitko, Carrie L.; Bickley, Daniel; Krijanovski, Oleg; Reddy, Pavan; Yanik, Gregory; Ferrara, James L M.

In: Blood, Vol. 111, No. 4, 15.02.2008, p. 2470-2475.

Research output: Contribution to journalArticle

Levine, JE, Paczesny, S, Mineishi, S, Braun, T, Choi, SW, Hutchinson, RJ, Jones, D, Khaled, Y, Kitko, CL, Bickley, D, Krijanovski, O, Reddy, P, Yanik, G & Ferrara, JLM 2008, 'Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease', Blood, vol. 111, no. 4, pp. 2470-2475. https://doi.org/10.1182/blood-2007-09-112987
Levine, John E. ; Paczesny, Sophie ; Mineishi, Shin ; Braun, Thomas ; Choi, Sung W. ; Hutchinson, Raymond J. ; Jones, Dawn ; Khaled, Yasser ; Kitko, Carrie L. ; Bickley, Daniel ; Krijanovski, Oleg ; Reddy, Pavan ; Yanik, Gregory ; Ferrara, James L M. / Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. In: Blood. 2008 ; Vol. 111, No. 4. pp. 2470-2475.
@article{8d60784e6c384a2680aef7b6cd0905e5,
title = "Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease",
abstract = "Graft-versus-host disease (GVHD) is a principal cause of morbidity following allogeneic hematopoietic cell transplantation (HCT). Standard therapy for GVHD, high-dose steroids, results in complete responses (CRs) in 35{\%} of patients. Because tumor necrosis factor-α (TNFα) is an important effector of experimental GVHD, we treated patients with newonset GVHD with steroids plus the TNFα inhibitor etanercept on a previously reported pilot trial (n = 20) and a phase 2 trial (n = 41). We compared their outcomes with those of contemporaneous patients with GVHD (n = 99) whose initial therapy was steroids alone. Groups were similar with respect to age, conditioning, donor, degree of HLA match, and severity of GVHD at onset. Patients treated with etanercept were more likely to achieve CR than were patients treated with steroids alone (69{\%} vs 33{\%}; P <.001). This difference was observed in HCT recipients of both related donors (79{\%} vs 39{\%}; P = .001) and unrelated donors (53{\%} vs 26{\%}; P <.001). Plasma TNFR1 levels, a biomarker for GVHD activity, were elevated at GVHD onset and decreased significantly only in patients with CR. We conclude that etanercept plus steroids as initial therapy for acute GVHD results in a substantial majority of CRs. This trial was referenced at www.clinicaltrials.gov as NCT00141713.",
author = "Levine, {John E.} and Sophie Paczesny and Shin Mineishi and Thomas Braun and Choi, {Sung W.} and Hutchinson, {Raymond J.} and Dawn Jones and Yasser Khaled and Kitko, {Carrie L.} and Daniel Bickley and Oleg Krijanovski and Pavan Reddy and Gregory Yanik and Ferrara, {James L M}",
year = "2008",
month = "2",
day = "15",
doi = "10.1182/blood-2007-09-112987",
language = "English (US)",
volume = "111",
pages = "2470--2475",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease

AU - Levine, John E.

AU - Paczesny, Sophie

AU - Mineishi, Shin

AU - Braun, Thomas

AU - Choi, Sung W.

AU - Hutchinson, Raymond J.

AU - Jones, Dawn

AU - Khaled, Yasser

AU - Kitko, Carrie L.

AU - Bickley, Daniel

AU - Krijanovski, Oleg

AU - Reddy, Pavan

AU - Yanik, Gregory

AU - Ferrara, James L M

PY - 2008/2/15

Y1 - 2008/2/15

N2 - Graft-versus-host disease (GVHD) is a principal cause of morbidity following allogeneic hematopoietic cell transplantation (HCT). Standard therapy for GVHD, high-dose steroids, results in complete responses (CRs) in 35% of patients. Because tumor necrosis factor-α (TNFα) is an important effector of experimental GVHD, we treated patients with newonset GVHD with steroids plus the TNFα inhibitor etanercept on a previously reported pilot trial (n = 20) and a phase 2 trial (n = 41). We compared their outcomes with those of contemporaneous patients with GVHD (n = 99) whose initial therapy was steroids alone. Groups were similar with respect to age, conditioning, donor, degree of HLA match, and severity of GVHD at onset. Patients treated with etanercept were more likely to achieve CR than were patients treated with steroids alone (69% vs 33%; P <.001). This difference was observed in HCT recipients of both related donors (79% vs 39%; P = .001) and unrelated donors (53% vs 26%; P <.001). Plasma TNFR1 levels, a biomarker for GVHD activity, were elevated at GVHD onset and decreased significantly only in patients with CR. We conclude that etanercept plus steroids as initial therapy for acute GVHD results in a substantial majority of CRs. This trial was referenced at www.clinicaltrials.gov as NCT00141713.

AB - Graft-versus-host disease (GVHD) is a principal cause of morbidity following allogeneic hematopoietic cell transplantation (HCT). Standard therapy for GVHD, high-dose steroids, results in complete responses (CRs) in 35% of patients. Because tumor necrosis factor-α (TNFα) is an important effector of experimental GVHD, we treated patients with newonset GVHD with steroids plus the TNFα inhibitor etanercept on a previously reported pilot trial (n = 20) and a phase 2 trial (n = 41). We compared their outcomes with those of contemporaneous patients with GVHD (n = 99) whose initial therapy was steroids alone. Groups were similar with respect to age, conditioning, donor, degree of HLA match, and severity of GVHD at onset. Patients treated with etanercept were more likely to achieve CR than were patients treated with steroids alone (69% vs 33%; P <.001). This difference was observed in HCT recipients of both related donors (79% vs 39%; P = .001) and unrelated donors (53% vs 26%; P <.001). Plasma TNFR1 levels, a biomarker for GVHD activity, were elevated at GVHD onset and decreased significantly only in patients with CR. We conclude that etanercept plus steroids as initial therapy for acute GVHD results in a substantial majority of CRs. This trial was referenced at www.clinicaltrials.gov as NCT00141713.

UR - http://www.scopus.com/inward/record.url?scp=41349118744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41349118744&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-09-112987

DO - 10.1182/blood-2007-09-112987

M3 - Article

C2 - 18042798

AN - SCOPUS:41349118744

VL - 111

SP - 2470

EP - 2475

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -